Login to Your Account

Pharma: Clinic Roundup

Tuesday, March 12, 2013

• Pfizer Inc., of New York, said the REMINDER trial of Inspra (eplerenone) showed statistically significant risk reductions in the primary composite efficacy endpoint, defined as time to first event of cardiovascular mortality, re-hospitalization or extended initial hospital stay due to diagnosis of heart failure (HF), sustained ventricular tachycardia or fibrillation, ejection fraction (EF) </= 40 percent after one month or an elevation of BNP/NT-proBNP after one month.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription